Related Experiment Video
Updated: Apr 27, 2026

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
[Inhibitory effect of kukoamine B on lung inflammatory responses in mice with sepsis]
Jinli Zhang1, Weiting Qin, Wanghui Lyu
1Department of Burns and Plastic Surgery, Affiliated Hospital, Jiangsu University, Zhenjiang 212001, Jiangsu, China. Corresponding author: Sun Bingwei,
Objective:
To investigate the inhibitory effect of kukoamine B (KB) on lung inflammatory responses in mice with sepsis and its possible molecular mechanism.
Methods:
Twenty-eight male mice were randomly divided into control group (n=8), lipopolysaccharide (LPS) group (n=10), and LPS + KB group (n=10). Sepsis model was reproduced by intra-peritoneal injection of 20 mg/kg LPS, while equivalent normal saline was given in control group, and 20 μg/kg KB was injected through caudal vein 4 hours after LPS challenge in LPS + KB group. After 8 hours of LPS challenge, the concentration of LPS in plasma and the activity of myeloperoxidase (MPO) in the lung tissue were determined. The contents of tumor necrosis factor-α (TNF-α) and interleukin-1β(IL-1β) in plasma, alveolar lavage fluid and lung tissue homogenates were assessed by enzyme linked immunosorbent assay (ELISA). The activation of nuclear factor-ΚB (NF-ΚB) and the expression of inducible nitric oxide synthase (iNOS) in lung tissue were determined by Western Blot. The pathological changes in lung tissues were observed with hematoxylin-eosin (HE) staining. The expression of intercellular adhesion molecule-1 (ICAM-1) in lung tissue was determined by immunohistochemistry.
Results:
Compared with control group, the concentration of LPS in plasma (1 155.650±147.149 kEU/L vs. 31.390±18.859 kEU/L), MPO activity (1.177±0.093 U/g vs. 0.775±0.166 U/g), NF-ΚB activity (gray value: 1.557±0.105 vs. 0.824±0.032) and the expression of iNOS (gray value: 0.650±0.129 vs. 0.392±0.097) were significantly increased in LPS group (all P<0.05). After KB intervention, the concentration of LPS (624.461±149.012 kEU/L), MPO activity (0.919±0.023 U/g), NF-ΚB activity (1.127±0.074) and the expression of iNOS (0.425±0.066) were significantly lowered (all P<0.05). Compared with control group, the contents of TNF-α (47.325±13.864 ng/L vs. 6.534±0.544 ng/L, 13.382±2.231 ng/L vs. 3.748±0.692 ng/L, 31.127±7.399 ng/L vs. 14.948±4.673 ng/L) and IL-1β (74.329±11.890 ng/L vs. 29.921±6.487 ng/L, 9.422±2.674 ng/L vs. 1.105±0.364 ng/L, 528.509±32.073 ng/L vs. 109.945±13.561 ng/L) in plasma, alveolar lavage fluid and lung tissue homogenates were obviously enhanced in LPS group (all P<0.05). With KB intervention, the contents of TNF-α (20.331±7.789 ng/L, 7.145±1.202 ng/L, 15.966±2.946 ng/L) and IL-1β (57.707±8.098 ng/L, 2.212±0.878 ng/L, 426.154±11.270 ng/L) were markedly reduced (plasma TNF-α: F=16.052, P=0.002; IL-1β: F=20.649, P=0.000; lung tissue homogenates TNF-α: F=31.134, P=0.001; IL-1β: F=22.792, P=0.002; alveolar lavage fluid TNF-α: F=10.013, P=0.009; IL-1β: F=319.857, P=0.000). In addition, leukocyte infiltration to the lung tissue was attenuated, and the expression of ICAM-1 was reduced by KB in histological examination.
Conclusions:
KB, as a neutralizer of LPS, can inhibit the release of inflammatory mediators, reduce the pulmonary inflammatory response and protect the function of lung in septic mice.
Insights
Kukoamine B (KB) effectively neutralizes lipopolysaccharide (LPS) to reduce lung inflammation in septic mice. This study shows KB inhibits inflammatory mediators and protects lung function, offering a potential therapeutic strategy.
Area of Science:
- Pharmacology and Toxicology
- Immunology
- Sepsis Research
Context:
- Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, often leading to organ damage, particularly in the lungs.
- Lipopolysaccharide (LPS) is a major component of Gram-negative bacteria that triggers potent inflammatory responses, contributing to sepsis-induced lung injury.
- Kukoamine B (KB) is a compound being investigated for its potential anti-inflammatory properties.
Purpose:
- To evaluate the inhibitory effects of Kukoamine B (KB) on lung inflammatory responses in a mouse model of sepsis.
- To elucidate the molecular mechanisms underlying KB's protective effects against sepsis-induced lung inflammation.
Summary:
- Sepsis was induced in mice using lipopolysaccharide (LPS). Kukoamine B (KB) was administered to assess its impact on inflammatory markers and lung tissue.
- KB treatment significantly reduced LPS levels, myeloperoxidase activity, and the expression of nuclear factor-kappa B (NF-κB) and inducible nitric oxide synthase (iNOS) in lung tissue.
- KB also decreased the levels of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) in plasma, bronchoalveolar lavage fluid, and lung homogenates. Histological analysis revealed attenuated leukocyte infiltration and reduced intercellular adhesion molecule-1 (ICAM-1) expression in the lungs of KB-treated mice.
Impact:
- Kukoamine B demonstrates significant potential in mitigating LPS-induced lung inflammation and protecting lung function in a sepsis model.
- The findings suggest KB acts by neutralizing LPS, inhibiting inflammatory mediator release, and reducing NF-κB pathway activation.
- KB represents a promising therapeutic candidate for managing sepsis-induced pulmonary complications.

